Form 8-K - Current report:
SEC Accession No. 0001213900-25-026285
Filing Date
2025-03-31
Accepted
2025-03-31 16:22:14
Documents
15
Period of Report
2025-03-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0236414-8k_enzobio.htm   iXBRL 8-K 29181
2 PRESS RELEASE OF ENZO BIOCHEM, INC. DATED MARCH 28, 2025 ea023641401ex99-1_enzobio.htm EX-99.1 7845
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3740
  Complete submission text file 0001213900-25-026285.txt   218980

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enz-20250328.xsd EX-101.SCH 2999
5 XBRL LABEL FILE enz-20250328_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE enz-20250328_pre.xml EX-101.PRE 22349
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0236414-8k_enzobio_htm.xml XML 3561
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Filer) CIK: 0000316253 (see all company filings)

EIN.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-09974 | Film No.: 25793601
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)